Table 4.
Multivariable analysis of VEGF and IL-8 polymorphisms and time to recurrence
| n | Adjusted RR (95% CI)a | Adjusted P value | |
| VEGF C+936T | |||
| C/C (unfavorable) | 80 (66.1%) | 1 (reference) | <0.001 |
| C/T, T/T (favorable) | 41 (33.9%) | 0.28 (0.12, 0.64) | |
| IL-8 T−251A | |||
| T/T, T/A (favorable) | 98 (81%) | 1 (reference) | 0.030 |
| A/A (unfavorable) | 23 (19%) | 2.24 (1.12, 4.47) | |
| Combinedb | |||
| 2 favorable | 33 (27.3%) | 1 (reference) | <0.001 |
| 1 favorable | 73 (60.3%) | 5.04 (1.69, 15.0) | |
| 0 favorable | 15 (12.4%) | 9.45 (2.74, 32.6) |
a
Based on Cox proportional hazards model, stratified by race, number of resected lymph nodes and type of adjuvant therapy, with two polymorphisms included.
b
Based on Cox proportional hazards model, stratified by race, number of resected lymph nodes and type of adjuvant therapy.
VEGF, vascular endothelial growth factor; IL-8; interleukin-8; CI, confidence interval; RR, response rate.